Chembio to Host Conference Call to Discuss Third Quarter 2013 Financial
Conference Call Scheduled for Thursday, November 7th at 4:30 p.m. Eastern Time
MEDFORD, N.Y., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), which develops, manufactures, markets and licenses
point-of-care diagnostic tests, announced today that the Company will release
financial results for the third quarter of 2013, after the close of the market
on Thursday, November 7, 2013. The Company's 10-Q and earnings press release
will be available immediately after 4:00 p.m. on our web site.
Lawrence A. Siebert, Chembio's president and chief executive officer, will
host an investment community conference call beginning at 4:30 p.m. Eastern
Time on Thursday, November 7, 2013, to discuss these results and to answer
questions. He will be joined by Richard Larkin, Chembio's chief financial
To participate on the conference call, please dial (877) 407-0778 from the
U.S. or (201) 689-8565 from outside the U.S. In addition, following the
completion of the call, a telephone replay will be accessible until November
14, 2013 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or
(201) 612-7415 from outside the U.S. and entering conference ID #:13572542.
The conference call may also be accessed via the internet at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171835. An archive of the
webcast will be available for 90 days on the Company's website at
Those interested in listening to the conference call live via the Internet may
do so by visiting the Investor Relations section of Chembio's website at
www.chembio.com. To listen to the live call, please go to the website 15
minutes prior to its start to register, download, and install the necessary
audio software. A replay will be available on the website for a limited time.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties.Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.
CONTACT: Susan Norcott
(631) 924-1135 Ext. 125
Vida Strategic Partners (investors)
Stephanie C. Diaz
Press spacebar to pause and continue. Press esc to stop.